Incendia Therapeutics Appoints Louis G. Lange to Board
Portfolio - People | Dec 11, 2024 | Breakout Ventures Associates L
Incendia Therapeutics, a biotechnology company focused on developing monoclonal antibody therapies to enhance cancer treatment, has announced the appointment of Dr. Louis G. Lange to its Board of Directors. Dr. Lange, a distinguished biotechnology investor and entrepreneur, is known for his significant contributions in guiding early-stage companies towards scientific breakthroughs. The appointment expands the Incendia Board to six directors. Dr. Lange has been a General Partner with Asset Management Ventures since 2009, specializing in investments within the healthcare sector. His involvement is expected to bring valuable insight to Incendia, as the company continues its clinical trials for PRTH-101, a therapy aimed at treating advanced solid tumors.
Sectors
- Biotechnology
- Healthcare
- Venture Capital
Geography
- United States – Incendia Therapeutics is located in Cambridge, Massachusetts, which places its activities within the United States.
Industry
- Biotechnology – The article primarily involves Incendia Therapeutics, a biotechnology company developing therapies for cancer treatment.
- Healthcare – The focus of Incendia Therapeutics on improving cancer treatment outcomes is a key aspect of the healthcare industry.
- Venture Capital – Dr. Louis G. Lange's role as an investor and General Partner at Asset Management Ventures links the article to the venture capital industry.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Incendia Therapeutics | Target Company | Company | A clinical-stage biotechnology company focused on novel monoclonal antibody therapies for cancer treatment. |
| Louis G. Lange | Board Member | Person | Renowned biotechnology investor and entrepreneur joining the Board of Directors at Incendia Therapeutics. |
| Michael Kauffman | Chairman of the Board | Person | Chairman of Incendia Therapeutics' Board of Directors and CEO of Nereid Therapeutics. |
| Wendye R. Robbins | CEO | Person | President and CEO of Incendia Therapeutics. |
| Breakout Ventures | PE Firm | Company | The PE firm with which Dr. Lange is associated as reported in the article headline. |
| Asset Management Ventures | Venture Capital Firm | Company | Dr. Lange is a General Partner at this venture capital firm investing in healthcare and technology. |